Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Urology"
DOI: 10.1007/s00345-022-03958-9
Abstract: To compare cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and Bacillus Calmette–Guérin (BCG) immunotherapy for T1 squamous bladder cancer (BCa). We retrospectively analysed 188 T1 high-grade squamous BCa patients treated… read more here.
Keywords: cancer; immediate radical; bladder; bcg immunotherapy ... See more keywords
Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical nutrition"
DOI: 10.1016/j.clnu.2021.10.019
Abstract: OBJECTIVE To investigate the predictors of response to intravesical Bacillus Calmette-Guerin (BCG) immunotherapy for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) patients. MATERIALS AND METHODS We retrospectively analyzed the clinicopathological data of 184 intermediate… read more here.
Keywords: rvfa; response intravesical; bcg immunotherapy; immunotherapy ... See more keywords
A Stochastic Optimal Control Model for BCG Immunotherapy in Superficial Bladder Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Mathematical Modelling of Natural Phenomena"
DOI: 10.1051/mmnp/201712507
Abstract: Urologic studies have reported in several papers that the optimal dose of Bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer, is still a subject of research. Our main goal from this paper, is to find… read more here.
Keywords: bcg immunotherapy; immunotherapy superficial; bladder cancer; superficial bladder ... See more keywords
Contemporary outcomes of bladder carcinoma in situ treated with an adequate BCG immunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "BJU international"
DOI: 10.1111/bju.15567
Abstract: OBJECTIVE To assess whether bacillus Calmette-Guérin (BCG) responsiveness after initiation of an adequate BCG treatment (at least five of six instillations of induction and at least two of three instillations of maintenance) impacts oncological outcomes… read more here.
Keywords: bcg immunotherapy; adequate bcg; bcg unresponsive; months iqr ... See more keywords
Baseline Cytokine Profiles of Tuberculin-Specific CD4+ T Cells in Non–Muscle-Invasive Bladder Cancer May Predict Outcomes of BCG Immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-18-0046
Abstract: BCG immunotherapy helps preserve the bladder after surgery to remove certain bladder cancers but fails in about 30% of patients. A cytokine-secretion test identifies those most likely to fail, enabling choice of alternative treatments. Intravesical… read more here.
Keywords: bcg immunotherapy; cd4 cells; bladder; recurrence free ... See more keywords
Bacillus Calmette-Guerin immunotherapy-increasing dose as a means of improving therapy?
Sign Up to like & getrecommendations! Published in 2017 at "Translational cancer research"
DOI: 10.21037/tcr.2017.01.25
Abstract: Bladder cancer is not life threatening but it is characterized by frequent recurrences which may progress to muscle invasive disease. The standard therapy for intermediate and high grade non muscle invasive bladder cancer is tumor… read more here.
Keywords: bcg immunotherapy; immunotherapy; bacillus calmette; calmette guerin ... See more keywords